English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  We previously demonstrated that nasal administration of periodontitis gene vaccine (pVAX1 -HA2-fimA ) or pVAX1 -HA2-fimA  plus IL-15 as adjuvant provoked protective immunity in the periodontal tissue of SD rats. This study evaluated the immune effect of pVAX1 -HA2-fimA  plus CpG-ODN 1826 as an adjuvant in the SD rat periodontitis models to improve the efficacy of the previously used vaccine.    Methods  Periodontitis was induced in maxillary second molars in SD rats receiving a ligature and infected with  Porphyromonas gingivalis . Forty-two SD rats were randomly assigned to six groups: A, control without  P. gingivalis ; B,  P. gingivalis  with saline; C,  P. gingivalis  with pVAX1; D,  P. gingivalis  with pVAX1 -HA2-fimA ; E,  P. gingivalis  with pVAX1 -HA2-fimA/IL-15 ; F,  P. gingivalis  with pVAX1 -HA2-fimA +CpG ODN 1826 (30 µg). The levels of FimA-specific and HA2-specific secretory IgA antibodies in the saliva of rats were measured by ELISA. The levels of COX-2 and RANKL were detected by immunohistochemical assay. Morphometric analysis was used to evaluate alveolar bone loss. Major organs were observed by HE staining.    Results  30 μg could be the optimal immunization dose for CpG-ODN 1826 and the levels of SIgA antibody were consistently higher in the pVAX1 -HA2-fimA +CpG-ODN 1826 (30 µg) group than in the other groups during weeks 1–8 ( P  < 0.05, except week 1 or 2). Morphometric analysis demonstrated that pVAX1 -HA2-fimA +CpG-ODN 1826 (30 µg) significantly reduced alveolar bone loss in ligated maxillary molars in group F compared with groups B–E ( P  < 0.05). Immunohistochemical assays revealed that the levels of COX-2 and RANKL were significantly lower in group F compared with groups B–E ( P  < 0.05). HE staining results of the major organs indicated that pVAX1 -HA2-fimA  with or without CpG-ODN 1826 was not toxic for in vivo use.    Conclusions  These results indicated that CpG-ODN 1826 (30 µg) could be used as an effective and safe mucosal adjuvant for pVAX1 -HA2-fimA  in SD rats since it could elicit mucosal SIgA responses and modulate COX-2 and RANKL production during weeks 1–8, thereby inhibiting inflammation and decreasing bone loss.

bmc oral health

CpG immunostimulatory oligodeoxynucleotide 1826 as a novel nasal ODN adjuvant enhanced the protective efficacy of the periodontitis gene vaccine in a periodontitis model in SD rats